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The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in
humans1. CV2CoV is a second-generation mRNA vaccine containing non-modified
nucleosides but with optimized non-coding regions and enhanced antigen
expression. Here we report the results of a head-to-head comparison of the
immunogenicity and protective efficacy of CVnCoV and CV2CoV in non-human
primates. We immunized 18 cynomolgus macaques with two doses of 12 μg lipid
nanoparticle-formulated CVnCoV or CV2CoV or with sham (n = 6 per group).
Compared with CVnCoV, CV2CoV induced substantially higher titres of binding and
neutralizing antibodies, memory B cell responses and T cell responses as well as more
potent neutralizing antibody responses against SARS-CoV-2 variants, including the
Delta variant. Moreover, CV2CoV was found to be comparably immunogenic to the
BNT162b2 (Pfizer) vaccine in macaques. Although CVnCoV provided partial
protection against SARS-CoV-2 challenge, CV2CoV afforded more robust protection
with markedly lower viral loads in the upper and lower respiratory tracts. Binding and
neutralizing antibody titres were correlated with protective efficacy. These data
demonstrate that optimization of non-coding regions can greatly improve the
immunogenicity and protective efficacy of a non-modified mRNA SARS-CoV-2 vaccine
in non-human primates.

Efficacy results in humans have recently been reported for the CVnCoV
(CureVac) mRNA vaccine in the phase 2b/3 HERALD trial in a population
that included multiple viral variants. In this trial, the observed vaccine
efficacy against symptomatic coronavirus disease 2019 (COVID-19) was
approximately 48% and 53% in the overall study population and in a
subgroup of participants 18–60 years of age, respectively1. CV2CoV is
a second-generation mRNA vaccine that incorporates modifications
of non-coding regions that were selected by empiric screening for
improved antigen expression2,3. Both CVnCoV and CV2CoV are based
on RNActive technology4–7 and consist of non-chemically modified
sequence-engineered mRNA without pseudouridine6–12. Both vaccines
encode the same full-length, pre-fusion stabilized severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein13,14 and are
encapsulated in lipid nanoparticles (LNPs) with identical composition. CV2CoV has been engineered with different non-coding regions
flanking the open reading frame, which have previously been shown to
improve transgene expression3 and protection against SARS-CoV-2 in

ACE2-transgenic mice2. Specifically, CV2CoV includes 5′ untranslated
region (UTR) HSD17B4 and 3′ UTR PSMB3 elements followed by a histone stem–loop motif and a poly(A) sequence (Fig. 1 and Methods). In
the present study, we make a head-to-head comparison of the immunogenicity and protective efficacy of CVnCoV and CV2CoV against
SARS-CoV-2 challenge in non-human primates.

Vaccine immunogenicity
We immunized 18 cynomolgus macaques intramuscularly with 12 µg
CVnCoV, 12 µg CV2CoV or sham vaccine (Fig. 1b). The animals were
primed at week 0 and were boosted at week 4. No clinical adverse
effects were observed following vaccination. To assess innate immune
responses, sera were isolated from all animals 24 h after the first vaccination to evaluate innate cytokine responses. CV2CoV induced higher
levels of IFNα2a, IP-10 and MIP-1 than CVnCoV (P = 0.0152, P = 0.0152
and P = 0.0411, respectively; Extended Data Fig. 1).
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Fig. 1 | Vaccine design and study schema. a, Designs of the CVnCoV and CV2CoV
mRNA vaccine candidates. Both vaccines are based on CureVac’s RNActive
platform and encode SARS-CoV-2 spike protein with di-proline mutations. The
vaccines differ in their unique non-coding regions, as shown. b, Non-human
primate vaccine study schema. Cynomolgus macaques were immunized
intramuscularly (i.m.) on day (D) 0 with CVnCoV (n = 6) or CV2CoV (n = 6) mRNA
vaccine or were designated as sham (n = 6). The animals were boosted at week 4
and were challenged at week (W) 8. Samples were collected weekly after
immunization and on days 0, 1, 2, 4, 7 and 10 after challenge for immunological
and virological assays. PP, K986P and V987P mutations; HSL, histone stem–loop.

Binding antibody responses were assessed by performing
receptor-binding domain (RBD)-specific enzyme-linked immunosorbent assays (ELISAs) at multiple time points following immunization15,16.
At week 2, binding antibody titres were detected only with CV2CoV
and not with CVnCoV, with median values of 25 (range, 25–25) and
799 (range, 82–2,010) for CVnCoV and CV2CoV, respectively (Fig. 2a).
One week after the week-4 boost, the antibody titres were increased in
both groups, with medians of 48 (range, 75–710) and 28,407 (range,
2,714–86,541) for CVnCoV and CV2CoV, respectively (Fig. 2a). By week 8,
the binding antibody titres had increased in the CVnCoV group but were
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still >50 times lower than those in the CV2CoV group (P = 0.0043), with
median values of 214 (range, 47–1,238) and 14,827 (range, 2,133–37,079),
respectively.
Neutralizing antibody responses were assessed by pseudovirus neutralization assay using the vaccine-matched SARS-CoV-2 wild-type
(WT) WA1/2020 strain15–17. The neutralizing antibody titres followed
a trend similar to that of the binding antibody titres (Fig. 2b). At week
2, neutralizing antibodies were detected only with CV2CoV and not
with CVnCoV, with median values of 20 (range, 20–20) and 131 (range,
62–578) for CVnCoV and CV2CoV, respectively (Fig. 2b). One week after
the week 4 boost, the neutralizing antibody titres were increased, with
median values of 55 (range, 20–302) and 15,827 (range, 3,985–81,081)
for CVnCoV and CV2CoV, respectively. By week 8, the neutralizing
antibody titres had increased in the CVnCoV group but were still >20
times lower than those in the CV2CoV group (P = 0.0022), with median
values of 196 (range, 20–405) and 4,752 (range, 414–6,793), respectively.
At week 6, the median pseudovirus neutralizing antibody titres
against the D614G, B.1.1.7 (Alpha) and B.1.351 (Beta) variants for CVnCoV were 121, 101 and 189, respectively, while they were 4,962, 1,813
and 755 for CV2CoV (Fig. 2c). The median pseudovirus neutralizing
antibody titres against the C.37 (Lambda), B.1.617.1 (Kappa) and B.1.617.2
(Delta) variants for CVnCoV were 516, 158 and 36, respectively, while
they were 1,195, 541 and 568 for CV2CoV (Extended Data Fig. 2). The
pseudovirus neutralizing antibody titres induced by CV2CoV were
higher than those induced by CVnCoV for the WT (WA1/2020), D614G,
B.1.1.7 (Alpha), B.1.351 (Beta), C.37 (Lambda), B.1.617.1 (Kappa) and
B.1.617.2 (Delta) strains (P = 0.0043, 0.0087, 0.0043, 0.1320, 0.026,
0.0022 and 0.0043, respectively). Taken together, these data show
that CV2CoV induces substantially higher pseudovirus neutralizing
antibody titres against SARS-CoV-2 variants than CVnCoV.
Live-virus neutralizing antibody titres18 were largely consistent
with those for the pseudovirus. The live-virus neutralizing antibody
responses elicited by CV2CoV were higher than those elicited by CVnCoV against the WA1/2020 and B.1.617.2 (Delta) strains (P = 0.0466 and
0.0152, respectively), with similar trends for B.1.1.7 (Alpha) and B.1.351
(Beta) (P = 0.0628 and 0.1450, respectively) (Fig. 2d).
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Fig. 2 | CV2CoV elicits high levels of binding and neutralizing antibody
responses in macaques. Animals (n = 6 per group) were vaccinated twice with
12 µg of CVnCoV or CV2CoV on day 0 and on day 28 or remained untreated as
negative controls (sham). a, b, Titres of RBD-binding antibodies (a) and
pseudovirus neutralizing antibodies (NAb) against the ancestral SARS-CoV-2
strain (b) were evaluated at different time points after the first (weeks 0, 1, 2 and 4)
and second (weeks 5, 6 and 8) vaccinations. c, d, Sera collected on day 42 (week 6)

B.1.1.7
(Alpha)

B.1.351
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were analysed for pseudovirus (c) and live-virus (d) neutralizing antibody titres
against virus with the D614G mutation and the B.1.1.7 (Alpha), B.1.351 (Beta) and
B.1.617.2 (Delta) variants. e, Sera collected from non-human primates immunized
with 12 µg of CVnCoV or 30 µg of BNT162b2 on day 35 (week 5) after boosting
were analysed for pseudovirus neutralizing antibody titres against the ancestral
WA/2020 (WT) strain. Each dot represents an individual animal and bars depict
the median; the dashed line shows the limit of detection.
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Fig. 3 | Protective efficacy of CV2CoV. Negative-control animals (sham) and
animals (n = 6 per group) vaccinated on day 0 and day 28 with 12 µg of CVnCoV
or CV2CoV were challenged with 1.0 × 105 TCID50 of SARS-CoV-2
(USA-WA1/2020) via the intranasal and intratracheal routes. a, b, BAL (a) and

nasal swab (b) samples collected on days 1, 2, 4, 7 and 10 after challenge were
analysed for levels of replicating virus by RT–PCR specific for sgRNA. Thin
black lines represent individual animals and thick red lines depict the median;
the dashed line shows the limit of detection.

We also compared the pseudovirus neutralizing antibody titres
induced in macaques by two immunizations with 12 μg of CV2CoV to
those induced by two immunizations with 30 μg of the Pfizer BNT162b2
clinical vaccine obtained as leftover product from pharmacies. At peak
immunity at week 5, the neutralizing antibody responses induced by
CV2CoV were comparable to those induced by BNT162b2 (Fig. 2e).
Most SARS-CoV-2 RBD-specific B cells reside within the memory B
cell pool19. We used flow cytometry to assess memory B cell responses
in the blood of non-human primates vaccinated with CVnCoV, CV2CoV
or sham20. Higher numbers of RBD-specific and spike-specific memory
B cells were detected in the CV2CoV-vaccinated animals as compared
with those vaccinated with CVnCoV at week 6 (P = 0.022 and P = 0.0152,
respectively) (Extended Data Fig. 3a, b). T cell responses were assessed
by interferon γ (IFNγ) and interleukin (IL)-4 enzyme-linked immunosorbent spot (ELISPOT) assay using pooled spike peptides at week 6.
IFNγ responses were detected in both groups but were higher in the
CV2CoV group (P = 0.0065) (Extended Data Fig. 3c). IL-4 responses
were not detectable, suggesting that CVnCoV and CV2CoV induce T
helper type 1-biased responses (Extended Data Fig. 3d).

2.40–6.61) log10-transformed sgRNA copies per ml in the BAL and 6.42
(range, 4.46–7.81) log10-transformed sgRNA copies per swab in the nasal
swab samples (Fig. 3). The CV2CoV-immunized animals exhibited peak
medians of 2.90 (range, 1.70–4.64) log10-transformed sgRNA copies
per ml in the BAL and 3.17 (range, 2.59–5.63) log10-transformed sgRNA
copies per swab in the nasal swab samples (Fig. 3), with resolution of
sgRNA levels in the BAL samples by day 2 in most animals and by day
4 in all animals. Overall, CV2CoV resulted in significantly lower peak
viral loads than CVnCoV in both the BAL (P = 0.0411) and nasal swab
(P = 0.0087) samples (Fig. 4a, b).
We next evaluated the immune correlates of protection. The
log10-transformed ELISA and neutralizing antibody titres at week 6
were inversely correlated with the peak log10-transformed sgRNA copies per ml in the BAL samples (P = 0.0008, R = −0.7148 and P = 0.0015,
R = −0.6912, respectively, by two-sided Spearman rank-correlation test)
(Fig. 4c, e) and with the peak sgRNA copies per nasal swab in the nasal
swab samples (P < 0.0001, R = −0.8346 and P < 0.0001, R = −0.8766,
respectively, by two-sided Spearman rank-correlation test) (Fig. 4d, f).
Consistent with prior observations from our laboratory and others15,16,22,
these findings suggest that binding and neutralizing antibody titres are
important correlates of protection for these SARS-CoV-2 vaccines in
non-human primates. Similar correlates of protection were observed
with viral loads assessed as area under the curve (Extended Data Fig. 4).
Moreover, we assessed infectious virus titres by TCID50 assay on day 2
after challenge, which showed no detectable virus in five of six animals
in the CV2CoV group (Extended Data Fig. 5).
Following challenge, we observed anamnestic binding and neutralizing antibody responses in all CVnCoV-vaccinated animals and in a subset
of the CV2CoV-vaccinated animals16 (Extended Data Fig. 6). On day 10
after challenge, the animals were necropsied, and their lung tissues were
evaluated by histopathology. Viral replication was largely resolved by
day 10 in the animals vaccinated with CVnCoV and CV2CoV, and those
with sham treatment had higher cumulative lung pathology scores19
(CVnCoV animals compared with sham controls, P = 0.0368; CV2CoV

Protective efficacy
All animals were challenged at week 8 with 1.0 × 105 median tissue culture infectious doses (TCID50) of the SARS-CoV-2 WA1/2020 strain via
the intranasal and intratracheal routes. Viral loads were assessed in
bronchoalveolar lavage (BAL) and nasal swab samples collected on days
1, 2, 4, 7 and 10 following challenge by quantitative PCR with reverse
transcription (RT–PCR) specific for subgenomic RNA (sgRNA)21. The
sgRNA levels in the BAL and nasal swab samples in the sham group
peaked on day 2 and largely resolved by day 10. The sham controls
had peak medians of 6.02 (range, 4.62–6.81) log10-transformed sgRNA
copies per ml in the BAL and 7.35 (range, 5.84–8.09) log10-transformed
sgRNA copies per swab in the nasal swab samples on day 2 (Fig. 3). The
CVnCoV-immunized animals showed peak medians of 4.92 (range,
412 | Nature | Vol 601 | 20 January 2022
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Fig. 4 | Titres of binding and neutralizing antibodies elicited following
CVnCoV and CV2CoV vaccination (n = 6 per group) correlate with
protection against SARS-CoV-2. a, b, Summary of peak viral loads following
SARS-CoV-2 challenge in BAL and nasal swab (NS) samples. Animals were
challenged with 1.0 × 105 TCID50 of SARS-CoV-2 derived from strain

USA-WA1/2020 (NR-52281, BEI Resources). c–f, Antibody correlates of
protection for binding antibodies (c, d) and neutralizing antibodies (e, f).
Statistical analysis was performed using the two-tailed non-parametric
Mann–Whitney test, and correlation was analysed by two-sided Spearman
rank-correlation test. The bars indicate median values.

animals compared with sham controls, P = 0.0022) (Extended Data
Fig. 7a). Animals in the sham group also had more lung lobes affected
(Extended Data Fig. 7b) and more extensive lung lesions, with a greater
proportion of lung lobes showing evidence of interstitial inflammation,
alveolar inflammatory infiltrates and type II pneumocyte hyperplasia
(Extended Data Fig. 7c–h). No significant eosinophilia was observed.
The pathological lesions in vaccinated animals were similar to those
observed for animals in the sham group (Extended Data Fig. 7i–l) but
were overall fewer in number and more focal in distribution.

against multiple viral variants and provided >3 log reductions in sgRNA
copies per ml in BAL and >4 log reductions in sgRNA copies per swab
in nasal swab samples compared with sham controls.
Previous mRNA vaccine clinical trials have demonstrated onset of
protective efficacy after the first dose with improved protection after
the boost immunization25,26. In the present study, the prime immunization with CV2CoV induced binding and neutralizing antibodies in all
macaques by week 2, and these responses had increased substantially
by 1 week after the boost immunization. The neutralizing antibody
titres induced by CV2CoV in this study also appear to be similar to
those reported for other mRNA vaccines in macaques27,28. Moreover, the
neutralizing antibody titres induced by BNT162b2 in our study (Fig. 2e)
were comparable to those reported for BNT162b2 in a prior study28.
As previously reported for other vaccines29–33, the neutralizing antibody titres against certain SARS-CoV-2 variants, such as the B.1.351
(Beta) and B.1.617.2 (Delta) variants, were lower than those against the
parental strain WA1/2020. Although our challenge virus in this study
was SARS-CoV-2 WA1/2020, the neutralizing antibody titres elicited by
CV2CoV to viral variants exceeded the values we previously reported as
threshold titres for protection (50–100)17,19,22. However, future studies
will be required to directly assess the protective efficacy of CV2CoV
against SARS-CoV-2 variants of concern in non-human primates.
CV2CoV induced both antigen-specific memory B cell responses and
T cell responses. Although the correlates of protection in this study were
binding and neutralizing antibody titres34,35, it is likely that CD8+ T cells
contribute to viral clearance in tissues36,37. We previously reported
that depletion of CD8+ T cells partially abrogated protective efficacy
against SARS-CoV-2 re-challenge in convalescent macaques22. Memory
B cells might contribute to the durability of antibody responses38,39;
B cell germinal centre responses and the durability of protective efficacy
following CV2CoV vaccination remain to be determined. Moreover,

Discussion
CV2CoV elicited substantially greater humoral and cellular immune
responses and provided significantly improved protective efficacy
against SARS-CoV-2 challenge as compared with CVnCoV in macaques.
These data suggest that optimization of non-coding elements of the
mRNA backbone can substantially improve the immunogenicity and
protective efficacy of mRNA vaccines. Both CVnCoV and CV2CoV
contain only non-modified nucleosides with no pseudouridine or
derivates, and CV2CoV has previously been shown to lead to higher
antigen expression than CVnCoV in cell culture3. The neutralizing antibody titres induced by CV2CoV were comparable in macaques to those
induced by the clinical BNT162b2 vaccine, which incorporates pseudouridine. These results suggest that strategies other than nucleoside
modification can also markedly improve mRNA potency.
Previous studies with rodents and non-human primates have demonstrated protection by CVnCoV2,23,24. However, protection in macaques
was primarily observed in the lower respiratory tract23,24. In the present
study, CVnCoV provided only modest viral load reductions in BAL and
nasal swab samples compared with sham controls. In contrast to CVnCoV, CV2CoV induced >10-fold-higher neutralizing antibody responses
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although this study was not specifically designed as a safety study, it
is worth noting that we did not observe any adverse effects following
CVnCoV or CV2CoV vaccination, nor did we observe unexpected or
enhanced pathology in the vaccinated animals at necropsy40.
In summary, our data show that optimization of non-coding regions
in a SARS-CoV-2 mRNA vaccine can substantially improve its immunogenicity against multiple viral variants and can enhance its protective
efficacy against SARS-CoV-2 challenge in macaques. The improved
characteristics of CV2CoV over those of CVnCoV might translate into
increased efficacy in humans; accordingly, clinical trials of CV2CoV
are planned.
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Methods
mRNA vaccines
The two mRNA vaccines, CVnCoV and CV2CoV, are based on CureVac’s
RNActive platform (claimed and described in, for example, patents
WO2002098443 and WO2012019780) and include no chemically
modified nucleosides. They are composed of a 5′ cap1 structure, a
G+C-enriched open reading frame, a 3′ UTR and a vector-encoded
poly(A) stretch. CVnCoV contains a cleanCap (Trilink) and parts of
the 3′ UTR of the Homo sapiens alpha-haemoglobin gene as the 3′
UTR, followed by a poly(A)64 stretch, a poly(C)30 stretch and a histone
stem–loop22,23. CV2CoV has previously been described and contains
a cleanCap followed by the 5′ UTR from the human hydroxysteroid 17-beta dehydrogenase 4 gene (HSD17B4) and a 3′ UTR from the
human proteasome 20S subunit beta 3 gene (PSMB3) followed by a
histone stem–loop and a poly(A)100 stretch3. The constructs were
encapsulated in LNP by Acuitas Therapeutics (CV2CoV) or Polymun Scientific Immunbiologische Forschung (CVnCoV). LNPs are
composed of ionizable amino lipid, phospholipid and cholesterol
and PEGylated lipid; the compositions for CVnCoV and CV2CoV are
identical. Both mRNAs encode SARS-CoV-2 full-length spike protein
containing stabilizing K986P and V987P mutations (NCBI reference
sequence NC045512.2).
Animals and study design
Eighteen cynomolgus macaques of both sexes between the ages of
3 and 20 years were randomly assigned to three groups. The animals
received either CVnCoV (n = 6) or CV2CoV (n = 6) mRNA vaccine or
were designated as sham controls (n = 6). The mRNA vaccines were
administered intramuscularly at a 12-µg dose in the left quadriceps on
day 0. Boost immunizations were similarly administered at week 4. At
week 8, all animals were challenged with 1.0 × 105 TCID50 of SARS-CoV-2
derived from USA-WA1/2020 (NR-52281, BEI Resources)17. The challenge
virus was administered as 1 ml by the intranasal route (0.5 ml in each
naris) and 1 ml by the intratracheal route. All animals were killed 10 d
after challenge. Immunological and virological assays were performed
with blinding. All animals were housed at Bioqual. All animal studies
were conducted in compliance with all relevant local, state and federal
regulations and were approved by the Bioqual Institutional Animal
Care and Use Committee.
Cytokine analyses
The serum levels of 19 analytes that have been associated with immune
response to viral infection were tested using the U-PLEX Viral Combo
1 (NHP) kit (K15069L-1) obtained from Meso Scale Discovery. The 19
analytes and their detection limits (LLODs) included G-CSF (1.5 pg ml−1),
GM-CSF (0.12 pg ml−1), IFNα2a (1.7 pg ml−1), IFNγ (1.7 pg ml−1), IL-1RA
(1.7 pg ml−1), IL-1β (0.15 pg ml−1), IL-4 (0.06 pg ml−1), IL-5 (0.24 pg ml−1),
IL-6 (0.33 pg ml−1), IL-7 (1.5 pg ml−1), IL-8 (0.15 pg ml−1), IL-9 (0.14 pg ml−1),
IL-10 (0.14 pg ml−1), IL-12p70 (0.54 pg ml−1), IP-10 (0.49 pg ml−1), MCP-1
(0.74 pg ml−1), MIP-1α (7.7 pg ml−1), TNF (0.54 pg ml−1) and VEGF-A
(2.0 pg ml−1). All serum samples were assayed in duplicate. The assay
was performed by the Metabolism and Mitochondrial Research Core
(Beth Israel Deaconess Medical Center, Boston, MA) following the
manufacture’s instructions. The assay plates were read by a MESO
QuickPlex SQ 120 instrument, and the data were analysed using Discovery Workbench 4.0 software.
ELISA
RBD-specific binding antibodies were assessed by ELISA as described
previously16,17. In brief, 96-well plates were coated with 1 μg ml−1
SARS-CoV-2 RBD protein (40592-VNAH, Sino Biological) in 1× DPBS
and were incubated at 4 °C overnight. After incubation, the plates
were washed once with wash buffer (0.05% Tween-20 in 1× DPBS)
and were blocked with 350 μl casein block per well for 2–3 h at room

temperature. After incubation, the block solution was discarded,
and the plates were blotted dry. Serial dilutions of heat-inactivated
serum diluted in casein block were added to the wells, and the plates
were incubated for 1 h at room temperature. Next, the plates were
washed three times and were then incubated for 1 h with a 1:1,000
dilution of anti-macaque IgG HRP (NIH NHP Reagent Program) at
room temperature in the dark. The plates were then washed three
more times, and 100 μl of SeraCare KPL TMB SureBlue Start solution was added to each well; plate development was halted by the
addition of 100 μl of SeraCare KPL TMB Stop solution per well. The
absorbance at 450 nm was recorded using a VersaMax or Omega
microplate reader. The ELISA endpoint titres were defined as the
highest reciprocal serum dilution that yielded an absorbance >0.2,
and the log10 endpoint titres are reported. The immunological assays
were performed with blinding.

Pseudovirus neutralization assay
SARS-CoV-2 pseudoviruses encoding a luciferase reporter gene
were generated as described previously 15. In brief, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene) and spike
protein-encoding pcDNA3.1-SARS CoV-2 SΔCT plasmid of variants
were co-transfected into HEK293T cells by Lipofectamine 2000
(ThermoFisher Scientific). Pseudoviruses of SARS-CoV-2 variants
were generated by using the WA1/2020 strain (Wuhan/WIV04/2019;
GISAID accession ID, EPI_ISL_402124), the strain with a D614G mutation, the B.1.1.7 variant (GISAID accession ID, EPI_ISL_601443), the
B.1.351 variant (GISAID accession ID, EPI_ISL_712096), the C37 variant (GenBank ID, QRX62290), the B.1.671.1 variant (GISAID accession
ID, EPI_ISL_1384866) and the B.1.617.2 variant (GISAID accession ID,
EPI_ISL_2020950). Supernatants containing the pseudotype viruses,
which were purified by centrifugation and filtration with a 0.45-µm
filter, were collected 48 h after transfection. To determine the neutralization activity of the plasma or serum samples from the animals
studied, HEK293T-hACE2 cells were seeded in 96-well tissue culture
plates at a density of 1.75 × 104 cells per well overnight. Threefold serial
dilutions of heat-inactivated serum or plasma samples were prepared
and mixed with 50 µl of pseudovirus. The mixture was incubated at
37 °C for 1 h before being added to the HEK293T-hACE2 cells. The
cells were lysed 48 h after infection in Steady-Glo Luciferase Assay
buffer (Promega) according to the manufacturer’s instructions. The
SARS-CoV-2 neutralization titres were defined as the sample dilution
at which a 50% reduction in relative light units (RLU) was observed
relative to the average of the virus control wells.
Live-virus neutralization assay
Full-length SARS-CoV-2 WA1/2020, B.1.1.7, B.1.351 and B.1.617.2
viruses were designed to encode nanoluciferase (nLuc) and were
recovered via reverse genetics18. One day before the assay, Vero E6
USAMRID cells were plated at 20,000 cells per well in clear-bottomed,
black-walled plates. The cells were inspected to ensure confluency
on the day of the assay. The serum samples were tested at a starting
dilution of 1:20 and were serially diluted threefold for up to nine
dilution spots. The serially diluted serum samples were mixed with
diluted virus in an equal volume. The antibody–virus and virus-only
mixtures were then incubated at 37 °C with 5% CO2 for 1 h. After incubation, the serially diluted sera and virus-only controls were added
in duplicate to the cells at 75 plaque-forming units at 37 °C with 5%
CO2. The cells were lysed 24 h later, and the luciferase activity was
measured via Nano-Glo Luciferase Assay System (Promega) according
to the manufacturer’s specifications. The luminescence was measured by a Spectramax M3 plate reader (Molecular Devices). Virus
neutralization titres were defined as the sample dilution at which
a 50% reduction in RLU was observed relative to the average of the
virus control wells.
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B cell immunophenotyping
Fresh peripheral blood mononuclear cells were stained with Aqua live/
dead dye (Invitrogen) for 20 min, washed with 2% FBS in DPBS and
suspended in 2% FBS in DPBS with Fc Block (BD) for 10 min, followed by
staining with monoclonal antibodies against CD45 (clone D058-1283,
BUV805), CD3 (clone SP34.2, APC-Cy7), CD7 (clone M-T701, Alexa700),
CD123 (clone 6H6, Alexa700), CD11c (clone 3.9, Alexa700), CD20 (clone
2H7, PE-Cy5), IgA (goat polyclonal antibodies, APC), IgG (clone G18-145,
BUV737), IgM (clone G20-127, BUV396), IgD (goat polyclonal antibodies,
PE), CD80 (clone L307.4, BV786), CD95 (clone DX2, BV711), CD27 (clone
M-T271, BUV563), CD21 (clone B-ly4, BV605), CD14 (clone M5E2, BV570)
and CD138 (clone DL-101, PE-CF594). The cells were also stained for
SARS-CoV-2 antigens including biotinylated SARS-CoV-2 RBD protein
(Sino Biological) and full-length SARS-CoV-2 spike protein (Sino Biological) labelled with FITC and DyLight 405 (DyLight 405 Conjugation
Kit and FITC Conjugation Kit, Abcam) at 4 °C for 30 min. After staining,
the cells were washed twice with 2% FBS in DPBS, incubated with BV650
streptavidin (BD Pharmingen) for 10 min and then washed twice with
2% FBS in DPBS. After staining, the cells were washed and fixed with
2% paraformaldehyde. All data were acquired on a BD FACSymphony
flow cytometer. Subsequent analyses were performed using FlowJo
software (Treestar, v.9.9.6). The immunological assays were performed
with blinding.
IFNγ ELISPOT assay
ELISPOT plates were coated with mouse anti-human IFNγ monoclonal
antibody (BD Pharmingen) at a concentration of 5 μg per well overnight
at 4 °C. The plates were washed with DPBS containing 0.25% Tween20 and were blocked with R10 medium (RPMI with 11% FBS and 1.1%
penicillin–streptomycin) for 1 h at 37 °C. The S1 and S2 peptide pools
(custom made, JPT Peptide Technologies) used in the assay contained
peptides of 15 amino acids in length, overlapping by 11 amino acids, that
spanned the protein sequence and reflect the N-terminal and C-terminal
halves of the protein, respectively. The S1 and S2 peptide pools were
prepared at a concentration of 2 μg per well, and 200,000 cells per well
were added. The peptides and cells were incubated for 18–24 h at 37 °C.
All steps following this incubation were performed at room temperature. The plates were washed with ELISPOT wash buffer and were incubated for 2 h with 1 μg ml−1 rabbit polyclonal anti-human IFNγ biotin
obtained from U-Cytech. The plates were washed a second time and
were then incubated for 2 h with 1 μg ml−1 streptavidin–alkaline phosphatase antibody obtained from Southern Biotech. The final wash was
followed by the addition of nitro-blue tetrazolium chloride/5-bromo4-chloro 3′ indolyl phosphate p-toludine salt (NBT/BCIP chromagen)
substrate solution (ThermoFisher Scientific) for 7 min. The chromogen
was discarded, and the plates were washed with water and were dried
in a dim location for 24 h. The plates were then scanned and counted
using an ELISPOT analyser (Immunospot).
IL-4 ELISPOT assay
ELISPOT plates precoated with monoclonal antibody against IL-4
(Mabtech) were washed and blocked. The assay was then performed
as described above except that the development time with NBT/BCIP
chromagen substrate solution was 12 min.
Subgenomic RT–PCR assay
SARS-CoV-2 E gene sgRNA was assessed by RT–PCR using primers and
probes as previously described15,17. A standard was generated by first
synthesizing a gene fragment of the subgenomic E gene. The gene
fragment was subsequently cloned into the pcDNA3.1+ expression
plasmid using restriction site cloning (Integrated DNA Technologies).
The insert was transcribed in vitro to RNA using the AmpliCap-Max T7
High Yield Message Maker kit (CellScript). Log dilutions of the standard
were prepared for RT–PCR assays, ranging from 1 ×1010 copies to 1 ×10−1

copies. The viral loads were quantified from BAL fluid and nasal swab
samples. RNA extraction was performed on a QIAcube HT using the
IndiSpin QIAcube HT Pathogen kit according to the manufacturer’s
specifications (Qiagen). The standard dilutions and extracted RNA
samples were reverse-transcribed using SuperScript VILO Master
Mix (Invitrogen) following the cycling conditions described by the
manufacturer. A Taqman custom gene expression assay (ThermoFisher
Scientific) was designed using the sequences targeting the E gene
sgRNA. The sequences for the custom assay were as follows: forward
primer, sgLeadCoV2.Fwd: 5′-CGATCTCTTGTAGATCTGTTCTC-3′; E_
Sarbeco_R: 5′-ATATTGCAGCAGTACGCACACA-3′; E_Sarbeco_P1 (probe):
5′-VIC-ACACTAGCCATCCTTACTGCGCTTCG-MGBNFQ-3′. Reactions
were carried out in duplicate for samples and standards on QuantStudio 6 and 7 Flex Real-Time PCR systems (Applied Biosystems) with the
following thermal cycling conditions: initial denaturation at 95 °C for
20 s followed by 45 cycles of 95 °C for 1 s and 60 °C for 20 s. Standard
curves were used to calculate the sgRNA copies per millilitre or per
swab. The quantitative assay sensitivity was determined as 50 copies
per millilitre or per swab.

TCID50 assay
Vero TMPRSS2 cells (obtained from A. Creanga, NIH) were plated at
25,000 cells per well in DMEM with 10% FBS and gentamicin, and the
cultures were incubated at 37 °C, 5.0% CO2. Medium was aspirated and
replaced with 180 μl of DMEM with 2% FBS and gentamicin. Serial dilution of samples as well as positive (virus stock of known infectious titre)
and negative (medium only) controls were included in each assay. The
plates were incubated at 37 °C, 5.0% CO2, for 4 d, and the cell monolayers
were visually inspected for cytopathic effects. TCID50 was calculated
using the Read–Muench formula.
Histopathology
At the time of fixation, lungs were suffused with 10% formalin to expand
the alveoli. All tissues were fixed in 10% formalin and block-sectioned
at 5 µm. The slides were baked for 30–60 min at 65 °C, deparaffinized
in xylene, rehydrated through a series of graded ethanol to distilled
water and then stained with haematoxylin and eosin. Blinded histopathological evaluation was performed by a board-certified veterinary
pathologist (A.J.M.).
Statistical analyses
Statistical analyses were performed using GraphPad Prism (version 9.0)
software (GraphPad Software), and comparisons between groups were
performed using a two-tailed non-parametric Mann–Whitney U test.
P values of less than 0.05 were considered as significant. Correlations
were assessed by applying two-sided Spearman rank-correlation tests.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this paper.

Data availability
All data are available in the manuscript and its Supplementary Information. Source data are provided with this paper.
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Extended Data Fig. 1 | Innate cytokine induction following mRNA
immunization (6/group). Sera isolated 24h post first injection were analyzed
for a panel of 19 cytokines associated with viral infection using a U-PLEX Viral
Combo kit from Meso Scale Discovery. Changes in cytokine levels above the

detection limits were detectable for 9 cytokines. Each dot represents an
individual animal, bars depict the median and the dotted line shows limit of
detection. Statistical analysis was performed using two-tailed nonparametric
Mann-Whitney test.

Extended Data Fig. 2 | Neutralizing antibody titers against variants.
Animals (6/group) were vaccinated twice with 12µg of CVnCoV or CV2CoV on
d0 and d28 or remained untreated as negative controls (sham). Sera isolated on
d42 (week 6) were analyzed for pseudovirus neutralizing antibody titers

against C.37 (Lambda), B.1.617.1 (Kappa) and B.1.617.2 (Delta) variants. Each dot
represents an individual animal, bars depict the median and the dotted line
shows limit of detection.
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Extended Data Fig. 3 | Memory B and T cell immune responses day 42
following immunization. PBMCs from negative control (sham), CVnCoV or
CV2CoV vaccinated animals (6/group) isolated on d42 of the experiment were
stained for (a) RBD and (b) Spike-specific activated memory B cells and
analyzed by high-parameter flow cytometry. IFNγ responses to pooled spike

peptides were analyzed via ELISPOT (c). Each dot represents an individual
animal, bars depict the median and the dotted line shows limit of detection.
Statistical analysis was performed using two-tailed nonparametric
Mann-Whitney test. PBMC = peripheral blood mononuclear cell; SFC = spot
forming cells.

Extended Data Fig. 4 | Binding and neutralizing antibody titers correlate
with protection against SARS-CoV-2. Summary of area under curve (AUC)
viral load values following SARS-CoV-2 challenge in BAL and nasal swab samples
(6/group) (a, b); antibody correlates of protection for binding antibodies

(c, d) and neutralizing antibodies (e, f). Statistical analysis was performed
using two-tailed nonparametric Mann-Whitney test. Correlations was analyzed
by two-sided Spearman rank-correlation test. NAbs = neutralizing antibodies,
BAL = bronchoalveolar lavage NS = nasal swab.
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Extended Data Fig. 5 | Infectious virus titers after SARS-CoV-2 challenge
(6/group). Infectious virus titers of BAL and nasal swab samples collected 2
days post challenge were analyzed by TCID50 assays. Each dot represents an

individual animal, bars depict the median and the dotted line shows limit of
detection. Statistical analysis was performed using two-tailed nonparametric
Mann-Whitney test.

Extended Data Fig. 6 | Post-challenge binding and neutralizing antibody
responses (6/group). Negative control (sham) or animals vaccinated on d0
and d28 of the experiment with 12 µg of CVnCoV or CV2CoV as indicated were
subjected to challenge infection using 1.0×105 TCID50 SARS-CoV-2 via intranasal
(IN) and intratracheal (IT) routes. (a) Titers of RBD binding antibodies and

(b) pseudovirus neutralizing antibodies against ancestral SARS-CoV-2 strain
were evaluated before (week 8) and a week after challenge infection (week 9).
Each dot represents an individual animal, bars depict the median and the
dotted line shows limit of detection. Statistical analysis was performed using
two-tailed nonparametric Mann-Whitney test. NAbs = neutralizing antibodies.
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Extended Data Fig. 7 | CVnCoV and CV2CoV protect the lungs from
pathological changes upon viral challenge (6/group). Eight lung lobes (4
sections from right and left, caudal to cranial) were assessed and scored (1-4)
for each of the following lesions: 1) Interstitial inflammation and septal
thickening 2) Eosinophilic interstitial infiltrate 3) Neutrophilic interstitial
infiltrate 4) Hyaline membranes 5) Interstitial fibrosis 6) Alveolar infiltrate,
macrophage 7) Alveolar/Bronchoalveolar infiltrate, neutrophils 8) Syncytial
cells 9) Type II pneumocyte hyperplasia 10) Broncholar infiltrate, macrophage
11) Broncholar infiltrate, neutrophils 12) BALT hyperplasia 13) Bronchiolar/
peribronchiolar inflammation 14) Perivascular, mononuclear infiltrates 15)
Vessels, endothelialitis. Each feature assessed was assigned a score of 0 = no
significant findings; 1 = minimal; 2 = mild; 3 = moderate; 4 = marked/severe.

(a) Cumulative scores per animal (b) Cumulative scores per lung lobe.
Individual animals are represented by symbols. Representative histopathology
from sham vaccinated (c-h), CnVCoV vaccinated (i, j), and Cv2CoV vaccinated
(k, l) animals showing (c, d, inset) alveolar macrophage infiltrate, (e, f, inset)
syncytial cells (arrowheads) and type II pneumocyte hyperplasia, inset (g, h,
inset) bronchiolar epithelial necrosis with neutrophilic infiltrates (i) alveolar
neutrophilic infiltrate and alveolar septal thickening ( j) focal consolidation
with inflammation composed of macrophages, neutrophils, and syncytial cells
(k) focal pneumocyte hyperplasia, syncytial cells and inflammatory infiltrates
(l) peribronchiolar inflammation. Statistical analysis was performed using
two-tailed nonparametric Mann-Whitney test. Scale bars: 100 microns (c), 50
microns (e, g) 20 microns (i-l). BALT bronchus associated lymphoid tissue.
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